Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab in HER2-negative Breast Cancer with HER2+ Bone Marrow DTCs
NCT01779050Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2013
- Primary completion
- Sep 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in breast cancer, sponsored by Washington University School of Medicine. Started Dec 2013; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01779050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01779050.